BPC-157 for Sports Injuries: What a Systematic Review of the Evidence Actually Shows
A systematic review found promising preclinical evidence that BPC-157 promotes musculoskeletal healing, but human data remains almost nonexistent — just one small study of 12 patients.
Quick Facts
What This Study Found
This systematic review of 36 studies (35 preclinical, 1 clinical) found that BPC-157 enhances growth hormone receptor expression and promotes angiogenesis while reducing inflammatory cytokines. In animal models, BPC-157 improved functional, structural, and biomechanical outcomes across muscle, tendon, ligament, and bone injuries.
The sole clinical study was a retrospective review of 12 patients with chronic knee pain who received intraarticular BPC-157 injections — 7 of 12 reported pain relief lasting more than 6 months. BPC-157 has a half-life under 30 minutes, is metabolized in the liver, and cleared by the kidneys. No adverse effects were found in preclinical safety studies, but no clinical safety data exist.
Key Numbers
544 articles identified · 36 studies included · 35 preclinical, 1 clinical · 7/12 patients reported relief >6 months · half-life <30 minutes · studies spanning 1993–2024
How They Did This
Systematic review of English-language literature from PubMed, Cochrane, and Embase databases, from inception through June 2024. Two independent reviewers screened 544 articles in three phases, with disagreements resolved by group consensus and a third reviewer. PROSPERO was checked for existing or unpublished reviews. Thirty-six studies met inclusion criteria.
Why This Research Matters
BPC-157 is already widely used by athletes and clinicians despite having no FDA approval and being banned in professional sports. This review is the first systematic synthesis of the orthopaedic sports medicine literature, highlighting both the promising preclinical results and the near-total absence of human evidence — a gap that matters enormously given how many people are already using it.
The Bigger Picture
BPC-157 sits in an unusual spot: widely used in sports medicine and biohacking communities but supported almost entirely by animal research. This review makes that evidence gap impossible to ignore. While the preclinical data on tissue healing is genuinely promising, the leap from rat tendons to human joints hasn't been properly tested. The peptide's banned status in professional sports adds another layer of complexity for athletes considering it.
What This Study Doesn't Tell Us
Nearly all included studies (35 of 36) were preclinical animal research. The single clinical study was a small retrospective review of just 12 patients. No randomized controlled trials in humans were found. The review is limited to level IV and V evidence, and no clinical safety data exist. Manufacturing is unregulated, introducing contamination risks.
Questions This Raises
- ?Why haven't randomized controlled trials in humans been conducted despite decades of preclinical research and widespread off-label use?
- ?What are the long-term safety implications of repeated BPC-157 use, given that no clinical safety data exist?
- ?How do contamination risks from unregulated manufacturing affect real-world outcomes for athletes using BPC-157?
Trust & Context
- Key Stat:
- 35 of 36 studies were animal research Despite widespread human use, this systematic review found that nearly all BPC-157 evidence comes from preclinical models — only 12 patients have been studied in a clinical setting.
- Evidence Grade:
- Rated low because the review itself includes only level IV and V evidence — 35 preclinical studies and one small retrospective clinical study with no control group. No randomized controlled trials in humans were found.
- Study Age:
- Published in 2025 with literature searched through June 2024. This is the most current systematic review of BPC-157 in orthopaedic sports medicine available.
- Original Title:
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
- Published In:
- HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 15563316251355551 (2025)
- Authors:
- Vasireddi, Nikhil, Hahamyan, Henrik, Salata, Michael J, Karns, Michael, Calcei, Jacob G, Voos, James E, Apostolakos, John M
- Database ID:
- RPEP-13892
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Is BPC-157 approved by the FDA for treating sports injuries?
No. BPC-157 has no FDA approval for any indication, and its use is banned in professional sports. Despite this, it is increasingly used by clinicians and athletes for musculoskeletal injuries.
How strong is the human evidence for BPC-157 in injury recovery?
Very weak. Out of 36 studies reviewed, only one involved humans — a retrospective look at 12 patients with chronic knee pain. While 7 of 12 reported relief lasting over 6 months, this is far from the rigorous evidence needed to confirm effectiveness or safety.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13892APA
Vasireddi, Nikhil; Hahamyan, Henrik; Salata, Michael J; Karns, Michael; Calcei, Jacob G; Voos, James E; Apostolakos, John M. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 15563316251355551. https://doi.org/10.1177/15563316251355551
MLA
Vasireddi, Nikhil, et al. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.." HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025. https://doi.org/10.1177/15563316251355551
RethinkPeptides
RethinkPeptides Research Database. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Sy..." RPEP-13892. Retrieved from https://rethinkpeptides.com/research/vasireddi-2025-emerging-use-of-bpc157
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.